WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H533271
CAS#: 1298095-31-4
Description: K137 is a potent and competitive CK2 inhibitor.
Hodoodo Cat#: H533271
Name: K137
CAS#: 1298095-31-4
Chemical Formula: C10H10Br4N4
Exact Mass: 501.76
Molecular Weight: 505.834
Elemental Analysis: C, 23.74; H, 1.99; Br, 63.19; N, 11.08
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: K137; K-137; K 137
IUPAC/Chemical Name: N1-(4,5,6,7-Tetrabromo-1H-benzimidazol-2-yl)-propane-1,3-diamine
InChi Key: XOTCJGHQJDBEEH-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H10Br4N4/c11-4-5(12)7(14)9-8(6(4)13)17-10(18-9)16-3-1-2-15/h1-3,15H2,(H2,16,17,18)
SMILES Code: NCCCNC1=NC2=C(Br)C(Br)=C(Br)C(Br)=C2N1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Casein kinase II (CK2) is an ubiquitous and pleiotropic serine/threonine protein kinase able to phosphorylate hundreds of substrates. Being implicated in several human diseases, from neurodegeneration to cancer, the biological roles of CK2 have been intensively studied. Upregulation of CK2 has been shown to be critical to tumor progression, making this kinase an attractive target for cancer therapy.
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 505.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Cozza G, Zanin S, Sarno S, Costa E, Girardi C, Ribaudo G, Salvi M, Zagotto G, Ruzzene M, Pinna LA. Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity. Biochem J. 2015 Nov 1;471(3):415-30. doi: 10.1042/BJ20141127. Epub 2015 Sep 8. PMID: 26349539.